Latest Lixisenatide Stories
PARIS, April 30, 2015 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2015 Change Change
- Results support resubmission of U.S.
LUGANO, Switzerland and COPENHAGEN, Denmark, February 5, 2015 /PRNewswire/ -- - Elsiglutide is a GLP-2 receptor agonist with potential as a first-ever therapy to help cancer
DALLAS, December 10, 2014 /PRNewswire/ -- ReportsnReports.com adds Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study